Stock Ratings / Health Care / CTY / financials

HROW (71) MNKD (63) SPTX (56) JANX (33) ⌘ Pro Terminal →

City Therapeutics Inc. (CTY) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$22.14 +2.26% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $22.19

City Therapeutics Inc. (CTY) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $1.11B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $22.19 (+0.22%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.8% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CTY)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY CTY SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (25% of score)

FRED Regime × Technicals: 58% of 52W Range • RSI-14 at 61.6 (BULLISH MOMENTUM)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$21.46-3.2% Next Q

Q2 (-2Q)

Grade C$20.77+0.4% Next Q

Q3 (-1Q)

Grade C$20.86+6.1% Next Q

Current

Grade C-$22.14+0.5% Hist 90D α

Trajectory: C- (53) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CTY Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, CTY faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($21.74) or 200D SMA ($20.99) invalidates the momentum regime and cuts Target Base ($22.44) toward Bear Floor ($17.50).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CTY• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CTY Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How CTY Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$31.2M (0.8% FCF Margin)

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CTY)

✓Walkthrough of CTY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CTY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -1.16%

2026-10-30O $22.08H $22.26L $20.37C $22.14VOL 116.8K

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CTY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CTY Butterfly Map → + Track CTY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CTY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CTY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CTY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CTY)

Health Care Rank #187 of 1016 ⚔️ HROW vs CTY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CTY vs. HROW, MNKD, SPTX, JANX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, City Therapeutics Inc. (CTY) ranks #187 by composite RQD confidence (61/100, grade C-) and #350 by equity capitalization ($1.11B). Within this direct 5-issuer industry benchmark cohort, CTY leads on earnings valuation at N/A trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. HROW currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with CTY at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CTY ACTIVE City Therapeutics Inc.	C-	61/100	—	—	—	+2.26%	$1.11B	Benchmark Subject
HROW Harrow Inc.	B-	71/100	—	75.1%	42.9%	+2.04%	$1.12B	/hrow-vs-cty →
MNKD MannKind Corporation	C	63/100	—	92.3%	54.5%	+2.04%	$1.13B	/mnkd-vs-cty →
SPTX Seaport Therapeutics Inc.	D+	56/100	—	—	—	+3.53%	$1.13B	/sptx-vs-cty →
JANX Janux Therapeutics Inc.	E	33/100	—	—	-13.8%	-1.22%	$1.09B	/janx-vs-cty →

2. CTY Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

City Therapeutics Inc. (CTY) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $1.11B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. CTY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CTY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, City Therapeutics Inc. (NASDAQ: CTY) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $22.14 (+2.26% 1D, market cap $1.11B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, CTY ranks #187 in composite RQD confidence.

How does CTY compare to HROW and MNKD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CTY carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, HROW (Harrow Inc.) holds a B- grade (71/100 RQD, P/E N/A, ROIC 42.9%, cap $1.12B) and MNKD (MannKind Corporation) posts a C grade (63/100 RQD, P/E N/A, ROIC 54.5%, cap $1.13B). Among the 5-stock peer group, CTY leads on earnings multiple (N/A) while MNKD leads on capital efficiency (54.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CTY?

For City Therapeutics Inc. (CTY), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #187 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CTY trading relative to its 50-day, 200-day, and 52-week technical levels?

CTY last traded at $22.14 (+2.26% on volume of 130,928 shares), positioning the stock +1.84% above its 50-day simple moving average ($21.74) and +5.48% above its 200-day simple moving average ($20.99). Across its 52-week range of $19.75 to $23.88, CTY sits at the 57.9% percentile with a 14-day RSI of 61.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($19.37 to $24.91).

CTY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is City Therapeutics Inc. (CTY)?

In Trailing 12 Months, CTY converted $4.0B of revenue into a 52% gross margin, 27% operating margin, and $31.2M in free cash flow (0.8% FCF margin).

Direct Sub-Reports: CTY RQD Cockpit CTY 12M Forecast CTY Earnings & Move CTY Dividends & DRIP CTY Insiders & 13F CTY Whale Options CTY Profit Sankey CTY News & Why